Novaliq GmbH has announced the appointment of Christian Roesky, PhD, as the company’s chief executive officer. The former CEO Bernhard Günther will take on the new role of chief innovation officer. Roesky brings more than 15 years of eye care experience to Novaliq, having served many international pharmaceutical companies, including posts with Bausch + Lomb, Abbott and Novartis in Europe, according to a company press release.
At Hawaiian Eye, Audrey Talley Rostov, MD, explores evidence to guide intracameral antibiotic selection for use in cataract surgery to prevent postoperative endophthalmitis.
As the US population ages, can optometrists share the burden of age-related macular degeneration management while offering the same quality of care as ophthalmologists? Medscape Optometry
As the US population ages, can optometrists share the burden of age-related macular degeneration management while offering the same quality of care as ophthalmologists? Medscape Optometry
HEIDELBERG, Alemania–(BUSINESS WIRE)–Novaliq GmbH announced the appointment of Christian Roesky, PhD, as the company’s CEO, effective November 1, 2016. Former CEO Bernhard Gunther will take on the new role of Chief Innovation Officer.
The addition of intravitreal chemotherapy to strategies for treating retinoblastoma represents an improvement in management of the disease, according to a study. Researchers included 66 eyes of 66 patients with unilateral retinoblastoma from two treatm…